DAISY VO: Open Payments
NPI 1811331226 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,165 in 114 payments from 18 companies in 2025. Trend: 2023 $3,207 · 2024 $3,459 · 2025 $4,165
Food & beverage: $4,165
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $1,946 |
| Gilead Sciences, Inc. | 25 | $687 |
| Janssen Biotech, Inc. | 16 | $346 |
| Novo Nordisk Inc | 4 | $166 |
| Madrigal Pharmaceuticals | 1 | $142 |
| Aimmune Therapeutics, Inc. | 2 | $140 |
| Intra-Sana Laboratories | 7 | $136 |
| Ipsen Biopharmaceuticals, Inc | 5 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
Products named: SKYRIZI, RINVOQ, MAVYRET, TREMFYA, CREON, Wegovy, REZDIFFRA, ZENPEP.
Industry payments across NV — which companies pay providers there.
